Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. Abstract
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. Abstract
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722. Abstract
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. New Engl J Med. 2017;376:1527-1539. Abstract
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499. Abstract
ClinicalTrials.gov. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab. https://clinicaltrials.gov/ct2/show/NCT01663402. Accessed March 20, 2017.
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinologists guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017;23:1-87.
Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2016;39:2999-3058.
Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254. Abstract
Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563-572. Abstract
Marmot MG, Syme SL, Kagan A, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol. 1975;102:514-525. Abstract
Ueshima H, Okayama A, Saitoh S, et al. Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J Human Hypert. 2003;17:631-639.
Chiang CE, Ferrieres J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016;23:567-587. Abstract
Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. Abstract
Nakamura M, Uno K, Hirayama A, et al. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ Open. 2017;7:e014427.
Nakamura M. Exploration into lipid management and persistent risk in patients hospitalized for acute coronary syndrome in Japan (EXPLORE-J). Paper presented at: 81th Annual Scientific Meeting of the Japanese Circulation Society; March 2017; Kanagawa, Japan.
Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-1839. Abstract
Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112:3384-3390. Abstract
World Health Organization website. Priority noncommunicable diseases and conditions. Available at: http://www.wpro.who.int/health_research/documents/dhs_hr_health_in_asia_and_the_pacific_13_chapter_8_priority_noncommunicable_diseases_and_disorders.pdf. Accessed August 21, 2017.
Karthikeyan G, Theo KK, Islam S, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53:244-253. Abstract
Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin. 2009;25:431-447. Abstract
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68:92-125. Abstract
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-1297. Abstract
Kim HS, Wu Y, Lin SJ, et al. REALITY-Asia study. Curr Med Res Opin. 2008;24:1951-1963. Abstract
Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prevent Cardiol. 2011;19:781-794.
Pocock SJ, McMurray JJV, Collier TJ, et al. Making sense of statistics in clinical trial reports. Part 1 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66:2536-2549. Abstract
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA. 2016;316:2373-2384. Abstract

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Khung Keong Yeo, MBBS

Associate Professor (Adjunct); Senior Consultant Cardiologist, Department of Cardiology, National Heart Centre Singapore, Singapore

Disclosures

Disclosure: Khung Keong Yeo, MBBS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boston Scientific
Served as a speaker or a member of a speakers bureau for: Abbott Vascular; Amgen Inc.
Received grants for clinical research from: Medtronic, Inc.
Other: Abbott Vascular (Proctor)

Junya Ako, MD

Professor and Chairman, Department of Cardiovascular Medicine, Kitasato University, Sagamihara, Kanagawa, Japan

Disclosures

Disclosure: Junya Ako, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Abbott Vascular; Actelion Pharmaceuticals, Ltd; Amgen Inc.; Astellas Pharma, Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eisai Co., Ltd; JIMRO; Kaneka; Kyowa Hakko Kirin Co., Ltd.; Merck Sharp & Dohme Corp.; Mitsubishi Tanabe Pharma Corporation; Mochida; Ono Pharmaceutical Co., Ltd.; Pfizer Inc.; Sanofi; Shionogi & Co., Ltd.; St. Jude Medical; Sumitomo Dainippon Pharma; Takeda; Terumo Medical Corporation; Toa Eiyo; Volcano Corporation
Received grants for clinical research from: Abbott Vascular; Asahi Intec; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd; Japan Lifeline; Kowa Company Ltd.; Kyowa Hakko Kirin Co., Ltd.; Mediphysics; Mitsubishi Tanabe Pharma Corporation; Mochida; Ono Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Sumitomo Dainippon Pharma; Takeda; Teijin

David K. L. Quek, MBBS, FRCP, FESC, FACC

Senior Consultant Cardiologist, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Disclosures

Disclosure: David K. L. Quek, MBBS, FRCP, FESC, FACC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Menarini; Merck & Co., Inc.; Sanofi; Zuellig Pharma
Served as a speaker or a member of a speakers bureau for: Menarini; Merck & Co., Inc.; Pfizer Inc.; Sanofi; SERVIER

Tan Ru San, MBBS, MRCP

Senior Consultant, National Heart Centre Singapore, Singapore

Disclosures

Disclosure: Tan Ru San, MBBS, MRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Merck Sharp & Dohme Corp.
Served as a speaker or a member of a speakers bureau for: AstraZeneca

Editor

Walid Amara, MD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Servier
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier

Content Reviewer

Robert Morris, PharmD

Associate CME Clinical Director

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

High Risk Dyslipidemia Management in Asia Pacific

From Medscape Education

From High-Risk Dyslipidemia to CV Disease: It's Time to Improve Management

Authors: Khung Keong Yeo, MBBS; Junya Ako, MD; David K. L. Quek, MBBS, FRCP, FESC, FACC; Tan Ru San, MBBS, MRCPFaculty and Disclosures

processing....

None
中文

Posted: 11/9/2017

This educational activity is intended for an international audience of Asia-Pacific healthcare professionals, specifically cardiologists, diabetologists, endocrinologists, and primary care physicians involved in the management of patients with high-risk dyslipidemia.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Impact of dyslipidemia on cardiovascular (CV) events
- Latest clinical data on new lipid-lowering therapies, including proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, in patients with high-risk dyslipidemia, and particularly, familial hypercholesterolemia
Have greater competence related to
- The interpretation of statistics in clinical trials

Contents of This Activity

New Available Therapeutic Data in High-Risk Dyslipidemia

Dr Yeo presents recent data on lipid-lowering therapy in patients with high-risk dyslipidemia.
Khung Keong Yeo, MBBS

Atherosclerosis and High-Risk Dyslipidemia: Disease Burden in Asia Pacific and Unmet Needs

Dr Ako presents epidemiological data on CV events and dyslipidemia in Asia and identifies unmet needs.
Junya Ako, MD

Why Is It Important to Screen Asian Patients and to Reduce LDL Cholesterol?

Dr Quek presents the effects of hypercholesterolemia on CV events and LDL-C targets in different populations.
David K. L. Quek, MBBS, FRCP, FESC, FACC

Interpreting Statistics in Outcome Trials

Dr Ru San explains the importance of outcome trials and their interpretation.
Tan Ru San, MBBS, MRCP

Page 1 of 7

New Available Therapeutic Data in High-Risk Dyslipidemia

Download Slides

PDF Downloads

Web Reprint

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Khung Keong Yeo, MBBS

Junya Ako, MD

David K. L. Quek, MBBS, FRCP, FESC, FACC

Tan Ru San, MBBS, MRCP

Editor

Walid Amara, MD

Content Reviewer

Robert Morris, PharmD

From High-Risk Dyslipidemia to CV Disease: It's Time to Improve Management

Contents of This Activity

New Available Therapeutic Data in High-Risk Dyslipidemia

Atherosclerosis and High-Risk Dyslipidemia: Disease Burden in Asia Pacific and Unmet Needs

Why Is It Important to Screen Asian Patients and to Reduce LDL Cholesterol?

Interpreting Statistics in Outcome Trials

PDF Downloads